Controversial New Test Law In New jersey

16 January 1995

New legislation that took effect on January 1 in New Jersey, USA, requires insurers to cover a battery of tests including blood tests, Pap smears, mammograms, bowel and stool examinations and eye tests for glaucoma. The coverage would pay for some tests every year and others every two to five years, and would be available in combination with a basic package of coverage for doctors' visits and hospital stays.

The goal of the law is to combine these tests with a healthy way of life to reduce the long-term cost of health care as well as improve the wellbeing of state residents. It is based on a book by Donald Louria, chairman of the department of preventive medicine and community health at the University of Medicine and Dentistry of New Jersey. He says New Jersey is the first state to endorse a health strategy as official policy, adding that he has written to the governor and some legislators in the other 49 states to urge them to do so as well.

Need For The Law Disputed Insurers and others have questioned the need for the law, noting that some tests are already included in some coverage, and that they fear the creation of more bureaucracy. However, they also note that the state has not issued regulations stating that insurance companies must comply with the new law, nor have all three positions on the new health Wellness Promotion Advisory Board been filled yet; the Board will advise the legislature about changes in medical testing and service that might be better for consumers.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight